The importance of assessing and understanding myocardial scar and function in DMD has taken on increased clinical relevance with recent evidence that medical therapy with antifibrotic agents such as angiotensin converting enzyme inhibitors [8], angiotensin receptor blockers [26], and membrane sealants [27] may help prevent or slow the progression of cardiac disease in DMD. The gene discussed is ACE; the disease is Duchenne muscular dystrophy.